Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of MK-4305 in adults with primary insomnia (Study B)
2010-018414-69Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Insomnia comparing High-dose suvorexant with Placebo (2 arms). Primary endpoint: Change from baseline in mean subjective total sleep time at Month 1. Started Mar 2010; status: completed.
02
Drugs
suvorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2010-018414-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018414-69.